Log in

Ortho Regenerative Technologies Stock Price, News & Analysis (CNSX:ORTH)

Today's Range N/A
50-Day Range
$0.22
MA: $0.31
$0.37
52-Week Range N/A
Volume14,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ortho Regenerative Technologies Inc., an orthopedic and sports medicine technology company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for the treatment of rotator cuff tears; and Ortho-M, a freeze-dried formulation for the treatment of meniscus tears that are under the large animal studies. It also develops Ortho-C, a freeze-dried matrix for the treatment of articular cartilage; and Ortho-V, a freeze-dried biopolymer for the prevention of osteoarthritis pain that are under the feasibility studies. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-514-7820951

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ORTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ORTH and its competitors with MarketBeat's FREE daily newsletter.


Ortho Regenerative Technologies (CNSX:ORTH) Frequently Asked Questions

What is Ortho Regenerative Technologies' stock symbol?

Ortho Regenerative Technologies trades on the CNSX under the ticker symbol "ORTH."

Has Ortho Regenerative Technologies been receiving favorable news coverage?

Media headlines about ORTH stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ortho Regenerative Technologies earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Ortho Regenerative Technologies.

Who are some of Ortho Regenerative Technologies' key competitors?

Who are Ortho Regenerative Technologies' key executives?

Ortho Regenerative Technologies' management team includes the folowing people:
  • Dr. Brent Henry Barry Norton, Pres & Chief Exec. Officer
  • Mr. Luc Mainville M.B.A, Sr. VP & CFO (Age 55)
  • Prof. Michael Buschmann, Chief Scientific Officer, Corp. Sec. & Director (Age 57)
  • Benedek Simo, Controller

How do I buy shares of Ortho Regenerative Technologies?

Shares of ORTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ortho Regenerative Technologies' official website?

The official website for Ortho Regenerative Technologies is http://www.orthorti.com/.

How can I contact Ortho Regenerative Technologies?

Ortho Regenerative Technologies' mailing address is 16667 Hymus Blvd, KIRKLAND, QC H9H 4R9, Canada. The company can be reached via phone at +1-514-7820951.


MarketBeat Community Rating for Ortho Regenerative Technologies (CNSX ORTH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about Ortho Regenerative Technologies and other stocks. Vote "Outperform" if you believe ORTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel